Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia. Tadmor T, Levy Yurkovski I. Leuk Lymphoma 2024 Jan 22:1-4. doi: 10.1080/10428194.2024.2304026.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tadmor T, Levy Yurkovski I. Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia. Leuk Lymphoma 2024 Jan 22:1-4. doi: 10.1080/10428194.2024.2304026.
PMID: 38247446